Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer

M Svaton, M Zemanova, P Zemanova… - Anticancer …, 2020 - ar.iiarjournals.org
Aim: To investigate potential association between administration of corticosteroids, antibiotics,
probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins …

[HTML][HTML] The role of airway and endobronchial ultrasound in perioperative medicine

J Votruba, P Zemanová, L Lambert… - BioMed Research …, 2015 - hindawi.com
Recent years have witnessed an increased use of ultrasound in evaluation of the airway and
the lower parts of the respiratory system. Ultrasound examination is fast and reliable and …

Serious immune-related adverse events are associated with greater efficacy of nivolumab therapy against non-small cell lung cancer

…, J Kultan, M Hrnciarik, M Cernovska, P Zemanová… - in vivo, 2023 - iv.iiarjournals.org
Background/Aim: The aim of this study was to investigate possible association between
adverse events of nivolumab therapy and the effectiveness of treatment in patients with non-…

[HTML][HTML] Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors

L Krizova, I Benesova, P Zemanova, J Spacek… - Journal of Cancer …, 2024 - Springer
Purpose Immune checkpoint inhibitors (ICIs) dramatically changed the prognosis of patients
with NSCLC. Unfortunately, a reliable predictive biomarker is still missing. Commonly used …

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

…, J Krejci, M Zemanova, P Zemanova… - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab
are regimens used in combination with checkpoint inhibitors in non-squamous non-small …

Osimertinib v terapii pokročilého neskvamózního nemalobuněčného plicního karcinomu.

P Zemanová, M Zemanová - Remedia, 2022 - search.ebscohost.com
Zemanová P, Zemanová M. Osimertinib v terapii pokročilého neskvamózního
nemalobuněčného plicního karcinomu. Remedia 2022; … Petra Zemanová … LF UK a VFN …

Using forecasting methods for the bread consumption in the Czech Republic.

P Zemanová, D Strachotová, M Botek - 2018 - cabidigitallibrary.org
The paper deals with trends in consumption of bread as one of the basic foods. In general,
food production is growing steadily. However, the bakery industry experiences a decline in …

WITHDRAWN: New methods of brachyradiotherapy catheter stabilization in the airways

J Votruba, D Charouz, P Zemanova, J Benes… - 2018 - Elsevier
Accepted Manuscript WITHDRAWN: New methods of brachyradiotherapy catheter
stabilization in the airways Jiri Votruba, Dominik Charouz, Petra Zemanova, Jiri Benes, Vera …

P45. New method of brachytherapy catheter stabilization in proximal trachea

J Votruba, P Zemanova, J Benes - Translational Lung Cancer …, 2014 - ncbi.nlm.nih.gov
The authors describe the therapeutic management of a patient with implantation intratracheal
metastasis of carcinoma of the base of tongue and carcinoma in the left lower lobe. In …

[PDF][PDF] Náklady na diabetes 2. typu v podmínkách zdravotního systému České republiky

T Doležal, Z Písaříková, P Zemanová… - Vnitr Lek, 2009 - casopisvnitrnilekarstvi.cz
Analýza přímých zdravotních nákladů v podmínkách České republiky ukázala, že průměrné
roční náklady na jednoho di abetika 2. typu činí 25 858 Kč. Při vysoké prevalenci a incidenci …